Anti p jak2 y1007 1008

Manufactured by Cell Signaling Technology

Anti-p-JAK2 (Y1007/1008) is a laboratory reagent used to detect and quantify phosphorylated Janus Kinase 2 (JAK2) protein. It is a highly specific antibody that recognizes JAK2 phosphorylated at tyrosine residues 1007 and 1008, which are critical for JAK2 activation. This product can be used in various experimental techniques, such as Western blotting, immunoprecipitation, and immunohistochemistry, to study JAK2 signaling pathways.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using anti p jak2 y1007 1008

Detailed Antibody Reagents for Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

The antibodies anti-FABP4 (number ab92501), anti-JAK1 (number ab47435), anti-JAK3 (number ab45141), anti-STAT1 (number ab30645), anti-STAT3 (number ab76315), anti-SOCS1 (number ab9870), anti-SOCS2 (number ab3692), and anti-Rap1a (number ab197673) were purchased from Abcam (Cambridge, MA). Anti-Src (number 2108S), anti-p-Src family (Tyr416 number 6943S), anti-STAT2 (number 72604S), anti-JAK2 (number 3230S), anti-p-JAK2 (Y1007/1008, number 3771S), and anti-p-STAT2 (number 88410S) antibodies were obtained from Cell Signaling Technology (Danvers, MA), while anti-β-actin (number sc-8432) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).

Xu L., Zhang H., Wang Y., Yang A., Dong X., Gu L., Liu D., Ding N, & Jiang Y. (2021). FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE−/− mice atherosclerosis. Laboratory Investigation; a Journal of Technical Methods and Pathology, 102(1), 25-37.

+ Open protocol

+ Expand

Western Blotting of Cell Lysates

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lysate from cell lines and primary cells were subjected to SDS-PAGE and Western blotting as described previously (46 (link)). The antibodies used were anti-actin, anti-Myc, anti-C/EBPβ, anti-Alix, anti-Twist, and anti-CD63 (Santa Cruz Biotechnology); anti-GRB2 (Transduction Laboratories); anti-JAK2, anti-β-catenin, anti-FoxM1, anti-CDK6, anti–pJAK2^Y1007/1008, and anti-CCND2 (Cell Signaling Technology); anti-SET (Globozymes); anti-ABL (Ab-3), anti-CCND1/2, anti-PY (4G10), and anti-PP2Ac^Y307 (EMD); anti-hnRNPA1 (Abcam); and anti-Flag (M2; Sigma).

Silvestri G., Trotta R., Stramucci L., Ellis J.J., Harb J.G., Neviani P., Wang S., Eisfeld A.K., Walker C.J., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C.H., Stagno F., Vigneri P., Nteliopoulos G., May P.C., Reid A.G., Garzon R., Roy D.C., Moutuou M.M., Guimond M., Hokland P., Deininger M.W., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Polakova K.M., Zou Y., Fan X., Baer M.R., Calabretta B, & Perrotti D. (2020). Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery, 1(1), 48-67.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!